Maxim Group Analyst Discusses Ebola Virus (TKMR) (CYTX)

Maxim Group analyst Jason Kolbert discussed the Ebola virus in recent note. Companies mentioned in the report include Tekmira Pharma (NASDAQ: TKMR) and Cytori Therapeutics (NASDAQ: CYTX).

"In this industry report, we review the Biodefense Industry and the scope of some of the work (not all) going on in Ebola and Smallpox. We highlight several companies working on MCM (Medical Counter Measures), including Bavarian Nordic (BAVA), Mapp pharmaceuticals (private), SIGA (Nasdaq: SIGA), and MediVector (private)," said Kolbert.

"News that the FDA verbally communicated that it will downgrade the full clinical hold on TKM-Ebola to a partial hold, combined with concerns about the possible spread of the largest Ebola outbreak in history, sent Tekmira shares higher last Friday. While the FDA lift could pave the way for emergency use authorization (if needed) in the U.S., we believe the attention will highlight the depth and scope of the Biodefense industry and how companies like Tekmira might benefit," he added. "The ensuing Ebola outbreak and the danger that it poses to the United States and the rest of the world set the stage for regulatory action, along with the lack of adequate therapeutic agents against Ebola and the potential viability of TKM-Ebola as a treatment option."

Maxim has Buy ratings on Tekmira and Cytori Therapeutics.

For an analyst ratings summary and ratings history on Tekmira Pharma click here. For more ratings news on Tekmira Pharma click here.

Shares of Tekmira Pharma closed at $20.70 yesterday.

You May Also Be Interested In

• Chipotle Mexican Grill (CMG) PT Raised to $3,050 at Stephens
• WesBanco (WSBC) PT Lowered to $27 at Stephens
• Avery Dennison (AVY) PT Raised to $230 at Baird